Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 and Venetoclax for Acute Myeloid Leukemia
NCT05287568Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Dec 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of CC-486 in acute myeloid leukemia (AML) (3 cohorts), sponsored by University of Colorado Denver. Primary endpoint: Maximum Tolerated Dose at 7 years. Started Dec 2022; status: recruiting.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05287568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287568.